Evidence map›Paper›PMID 38151984›Full record

ArticleCancer medicine2024

Potentially functional genetic variants in ferroptosis-related CREB3 and GALNT14 genes predict survival of hepatitis B virus-related hepatocellular carcinoma.

Shicheng Zhan, Moqin Qiu, Xueyan Wei, Junjie Wei, Liming Qin, Binbin Jiang, Qiuping Wen, Peiqin Chen, Qiuling Lin, Xiaoxia Wei and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Journal of hepatocellular carcinoma · 2025
    Article
  3. Lasso-Cox interpretable model of AFP-negative hepatocellular carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  4. Article
  5. Comparison of the efficacy and safety of anlotinib monotherapy or anlotinib plus immune checkpoint inhibitor for advanced small cell lung cancer with brain metastases.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Shicheng ZhanDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0009-0007-2266-3939
Moqin QiuDepartment of Respiratory Oncology, Guangxi Medical University Cancer Hospital, Nanning, China.
Xueyan WeiDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0002-6053-2792
Junjie WeiDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Liming QinDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0003-4263-301X
Binbin JiangDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Qiuping WenDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Peiqin ChenEditorial Department of Chinese Journal of Oncology Prevention and Treatment, Guangxi Medical University Cancer Hospital, Nanning, China.
Qiuling LinDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0002-3239-4345
Xiaoxia WeiDepartment of Clinical Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Zihan ZhouDepartment of Cancer Prevention and Control, Guangxi Medical University Cancer Hospital, Nanning, China.ORCID 0000-0003-1444-4713
Yanji JiangScientific Research Department, Guangxi Medical University Cancer Hospital, Nanning, China.
Xiumei LiangDepartment of Disease Process Management, Guangxi Medical University Cancer Hospital, Nanning, China.
Runwei LiDepartment of Civil Engineering, College of Engineering, New Mexico State University, Las Cruces, New Mexico, USA.
Yingchun LiuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Hongping YuDepartment of Experimental Research, Guangxi Medical University Cancer Hospital, Nanning, China.
Guangxi Medical University · CNNew Mexico State University · US

Funding

Guangxi Medical and health appropriate Technology opening and popularization and application project S2022112Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor, Ministry of Education GKE-ZZ202104Natural Science Foundation of Guangxi Province 2023GXNSFBA026091Natural Science Foundation of Guangxi Province 2023GXNSFBA026201Youth Program of Scientific Research Foundation of Guangxi Medical University Cancer Hospital YQJ2022-5Youth Science Foundation of Guangxi Medical University GXMUYSF 202304Youth Science Foundation of Guangxi Medical University GXMUYSF 202312
6 · The paper itself

Abstract

backgroundFerroptosis is a known crucial player in the development of cancers. However, the effect of single nucleotide polymorphisms (SNPs) in ferroptosis-related genes on survival in hepatitis B virus (HBV)-related hepatocellular carcinoma (HBV-HCC) patients remains unknown.

methodsWe used two-stage multivariable Cox proportional hazards regression analyses to estimate the associations between 48,774 SNPs in 480 ferroptosis-related genes and overall survival (OS) of 866 HBV-HCC patients.

resultsWe identified that two potentially functional SNPs (CREB3 rs10814274 C > T and GALNT14 rs17010547 T > C) were significantly independently associated with the OS of HBV-HCC patients (CT + TT verse CC, hazards ratio (HR) = 0.77, 95% confidence interval (CI) = 0.67-0.89, p < 0.001 for rs10814274 and TC + CC verse TT, HR = 0.66, 95% CI = 0.53-0.82, p < 0.001 for rs17010547, respectively). Additional joint assessment of protective genotypes of these two SNPs showed that patients with 1-2 protective genotypes had a significantly better OS compared with those carrying 0 protective genotypes (HR = 0.56, 95% CI = 0.45-0.70, p < 0.001). Moreover, the expression quantitative trait loci (eQTL) analysis revealed that the survival-associated SNP rs10814274 T allele was significantly correlated with reduced CREB3 transcript levels in both normal liver tissues and whole blood cells, while the GALNT14 rs17010547 C allele had a significant correlation with increased GALNT14 transcript levels in whole blood cells.

conclusionThese results suggest that genetic variants of CREB3 and GALNT14 may affect the survival of HBV-HCC patients, likely via transcriptional regulation of respective genes. However, further studies are required to confirm these findings.

Indexed as

Carcinoma, HepatocellularCyclic AMP Response Element-Binding ProteinFerroptosisLiver NeoplasmsN-AcetylgalactosaminyltransferasesPolymorphism, Single NucleotideAgedFemaleHepatitis BHepatitis B virusHumansMaleMiddle AgedPrognosisCREB3 protein, humanCyclic AMP Response Element-Binding ProteinN-AcetylgalactosaminyltransferasesUDP-N-acetyl-D-galactosamine polypeptide N-acetylgalactosaminyltransferase 14, humanferroptosishepatocellular carcinomaoverall survivalsingle nucleotide polymorphism

Identifiers

PMID38151984
PMCPMC10807646
OpenAlexW4390341493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.